MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colin, S.
Right arrow Articles by Labarre, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colin, S.
Right arrow Articles by Labarre, J.

Vol. 55, Issue 1, 74-82, January 1999

In Vivo Involvement of Heparan Sulfate Proteoglycan in the Bioavailability, Internalization, and Catabolism of Exogenous Basic Fibroblast Growth Factor

Sylvie Colin, Jean-Claude Jeanny, Frederic Mascarelli, Raymond Vienet, Salman Al-Mahmood, Yves Courtois, and Jean Labarre

Service de Biochimie et Génétique Moléculaire, CEA Saclay, F 91191 Gif sur Yvette Cedex, France (S.C., J.L.); Institut National de la Santé de la Recherche Médicale U 450, Affiliée Centre National de la Recherche Scientifique, Association Claude-Bernard, Paris, France (J.-C.J., F.M., Y.C.); Service de Pharmacologie et Immunologie, CEA Saclay, F 91191 Gif sur Yvette Cedex, France (R.V.); and Laboratoire d'Oncologie, Hôpital Tarnier-Cochin, Paris, France (S.A.-M.)

The in vivo bioavailability of exogenous fibroblast growth factor 2 (FGF2) was studied after i.v. injection of uniformly 14C-labeled FGF2 into young rats. 14C-FGF2 was rapidly accumulated in almost all solid organs within 5 min. After 30 min, more than 65% of FGF2 was retained in liver, 4.5% in kidneys, 1.2% in spleen, 0.15% in adrenal glands, and trace amounts in bone marrow, eyes, lungs, and heart. Suborgan distribution of 14C-FGF2 showed that for kidneys and adrenal glands, the labeling was mainly concentrated in the cortical zone. Incubation of organ sections with 2 M NaCl or heparin eluted all the radioactivity, indicating that labeling was due to FGF2-heparan sulfate proteoglycan (HSPG) interactions. Electrophoretic analysis show only native 14C-FGF2 in the blood and extracellular matrix; however, FGF2 is continuously catabolized in solid organs, indicating that all participate in the clearance of FGF2 by cellular internalization and subsequent catabolism. All FGF2 catabolic fragments bound heparin, demonstrating the preservation of their HSPG-binding site during the in vivo intracellular catabolism of FGF2. Analysis of the high-affinity receptors of FGF2 (FGFR-1 and FGFR-3) and the mitogen-activated protein kinase did not show any increase in either FGFR tyrosine phosphorylation or in mitogen-activated protein kinase activation. This study shows for the first time that exogenous FGF2 is cleared by HSPG cellular internalization and catabolism without inducing the activation of FGFRs within at least five organs in vivo, which strongly suggests that the HSPG-dependent internalization and catabolism pathway may control the in vivo bioavailability of FGF2.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
X. Jiao, P. C. Billings, M. P. O'Connell, F. S. Kaplan, E. M. Shore, and D. L. Glaser
Heparan Sulfate Proteoglycans (HSPGs) Modulate BMP2 Osteogenic Bioactivity in C2C12 Cells
J. Biol. Chem., January 12, 2007; 282(2): 1080 - 1086.
[Abstract] [Full Text] [PDF]

Home page
 Biophys. JHome page
M. A. Dupree, S. R. Pollack, E. M. Levine, and C. T. Laurencin
Fibroblast Growth Factor 2 Induced Proliferation in Osteoblasts and Bone Marrow Stromal Cells: A Whole Cell Model
Biophys. J., October 15, 2006; 91(8): 3097 - 3112.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Wang, D. Li, H. Fan, L. Tian, Y. Zhong, Y. Zhang, L. Yuan, C. Jin, C. Yin, and D. Ma
Cellular Uptake of Exogenous Human PDCD5 Protein
J. Biol. Chem., August 25, 2006; 281(34): 24803 - 24817.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
R. Castelli, F. Porro, and P. Tarsia
The heparins and cancer: review of clinical trials and biological properties
Vascular Medicine, August 1, 2004; 9(3): 205 - 213.
[Abstract] [PDF]

Home page
 J. Cell Sci.Home page
L. Nadav, A. Eldor, O. Yacoby-Zeevi, E. Zamir, I. Pecker, N. Ilan, B. Geiger, I. Vlodavsky, and B.-Z. Katz
Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts
J. Cell Sci., May 15, 2002; 115(10): 2179 - 2187.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K. Ding, S. Sandgren, K. Mani, M. Belting, and L.-A. Fransson
Modulations of Glypican-1 Heparan Sulfate Structure by Inhibition of Endogenous Polyamine Synthesis. MAPPING OF SPERMINE-BINDING SITES AND HEPARANASE, HEPARIN LYASE, AND NITRIC OXIDE/NITRITE CLEAVAGE SITES
J. Biol. Chem., December 7, 2001; 276(50): 46779 - 46791.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
S. M. Smorenburg and C. J. F. Van Noorden
The Complex Effects of Heparins on Cancer Progression and Metastasis in Experimental Studies
Pharmacol. Rev., March 1, 2001; 53(1): 93 - 106.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. Shafiee, J. S. Penn, H. C. Krutzsch, J. K. Inman, D. D. Roberts, and D. A. Blake
Inhibition of Retinal Angiogenesis by Peptides Derived from Thrombospondin-1
Invest. Ophthalmol. Vis. Sci., July 1, 2000; 41(8): 2378 - 2388.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics